January 21, 2014 - Myeloma- Update on Research and Treatment from the American Society of Hematology (ASH®) Annual Meeting
- Current and emerging myeloma treatment options
- Updates on myeloma maintenance therapy
- The role of clinical trials in the advancement of treatment
- Advances in treatment side effects management
- Communicating with your healthcare team
Robert Z. Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor, Director, Myeloma Section
Departments of Lymphoma/Myeloma and Experimental Therapeutics
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Questions Asked by the Myeloma Community
- Please explain why myeloma is a blood cancer, not a bone cancer?
- Can you explain the P value (a measure of significance) seen in many of the slides?
- Is there any information on secondary cancers associated with lenalidomide (Revlimid®)?
- Will monoclonal antibodies be effective for smoldering myeloma?
- Is autologous stem cell transplantation still the standard of care?
- Can you address the use of curcumin, resveratrol and quercetin supplements in patients with smoldering multiple myeloma?
- What is your best guess about when an oral proteasome inhibitor (such as ixazomib) will be approved for Myeloma?
- Will the studies involving engineered T-cells, like the studies being held at the University of Pennsylvania be helpful for myeloma patients?
- Has there been progress in developing standard measurements for minimal residual disease (MRD)?
- What are the pluses and minuses of bortezomib (Velcade®) delivery, via subcutaneous injection versus IV administration?
- Is the major shortage of the drug Doxorubicin (Doxil®) affecting myeloma treatment?
- What does it mean if your lactate dehydrogenase (LDH) increases?
- Do you regularly use PET or CT scans for regular disease evaluation?
- How long can one safely take lenalidomide (Revlimid®)?
Sponsors and Supporters
This meeting is not sponsored, sanctioned by, or part of the 55th Annual Meeting of the American Society of Hematology.